AlphAIAlphAI — Financial news for AI agents
tradingview.com$EVAX

Evaxion A/S (EVAX) Reports EVX-01 T-Cell Responses and AI Prediction Association

Evaxion A/S reported phase 2 data for EVX-01, showing neoantigen-specific T-cell responses and significant AI prediction correlation (p<0.001) in advanced melanoma. This follows earlier clinical and immune-response data. Further clinical or regulatory progress would be a larger catalyst.

Original reporting
tradingview.com
Published Nov 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Evaxion A/S (EVAX) Reports EVX-01 T-Cell Responses and AI Prediction Association — source image
Source · tradingview.com
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The disclosed biomarker correlation (p<0.001) strengthens the scientific rationale for the program and could accelerate partnership talks.

02

Market read

First‑time release of statistically significant phase 2 data; may influence EVAX share price and sector sentiment.

03

What to watch

Regulatory timeline and manufacturing scalability for EVX‑01 remain uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

Evaxion A/S is a Danish biotech developing AI‑based cancer vaccines; EVX‑01 targets advanced melanoma.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion disclosed new phase 2 biomarker data showing neoantigen-specific T‑cells and a strong AI‑Immunology prediction correlation.

Expected impact

potential upside as investors price in reduced clinical risk

Evidence & confidence

First report of statistically significant biomarker data; biotech investors typically react positively to early‑stage efficacy signals.

Market effects

Sector

May boost confidence in AI‑driven immunotherapy platforms across biotech sector.

Regional

Positive for European biotech listings, especially Danish and Nordic peers.

Global

Highlights growing role of AI in drug discovery, relevant to global pharma investors.

Counterpoint

What could challenge this read

Biomarker data alone may not translate to clinical benefit; investors should await survival or response outcomes.

Key entities

  • company
    Evaxion A/S

    Developer of AI‑driven immunotherapy candidates.

Read at source← All news

StoryEvaxion reports 89% immune response rate for personalized melanoma vaccine in phase‑2 trial

Also covered by

1 outlet

Related articles

$EVAXMedAI 8/10

Evaxion: New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) presented phase 2 trial data for its personalized cancer vaccine EVX-01, showing strong immune responses in advanced melanoma patients. The data, shared at the SITC 2026 Annual Meeting, includes 89% vaccine target precision and sustained T-cell responses. Evaxion's AI-Immunology platform demonstrated strong predictive performance, with significant association between predictions and actual T-cell responses.

finanznachrichten.de
$EVAXMedAI 9/10

Evaxion presents phase 2 cancer vaccine biomarker data at SITC

Evaxion A/S (NASDAQ:EVAX) presented phase 2 trial data for its cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer Annual Meeting. The data showed significant T-cell responses and a strong association between its AI-Immunology platform's predictions and actual immune responses. The trial reported an Objective Response Rate of 75% in advanced melanoma patients.

investing.com
$EVAXMed

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S (NASDAQ: EVAX) will present new data on EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting. The data validate EVX-04's potential, showing broad patient coverage and immune response induction in preclinical models. EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens, selected using Evaxion's AI-Immunology platform.

finanznachrichten.de
$EVAXMedAI 8/10

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion (NASDAQ: EVAX) will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The trial, involving advanced melanoma patients, showed a 75% objective response rate. EVX-01 is designed with Evaxion's AI-Immunology platform and is being evaluated as a treatment for advanced melanoma.

finanznachrichten.de
$EVAXHighAI 8/10

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported 3-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The trial showed 89% of vaccine neoantigens generated specific T-cell responses, with sustained immune and clinical responses. The data will be presented at the ESMO 2026 Congress. Evaxion maintains a cash runway into 2027.

finanznachrichten.de